Log In Sign up
The largest database of trusted experimental protocols

Klrg 1 clone 13f12f2

Manufactured by Thermo Fisher Scientific
Visit Supplier

KLRG-1 (clone 13F12F2) is a monoclonal antibody that recognizes the killer cell lectin-like receptor G1 (KLRG1) surface antigen. KLRG1 is a marker expressed on natural killer cells, T cells, and other immune cell types. The antibody can be used for the identification and characterization of KLRG1-positive cells in various applications.

Automatically generated - may contain errors

Lab products found in correlation

Fixation permeabilization solution, by Thermo Fisher Scientific (2 mentions) Cd57 clone nk 1, by BD (2 mentions) Tim 3 clone 344823, by R&D Systems (2 mentions) Anti bcl 2 clone bcl 2 100, by BD (2 mentions) Anti ezh2 clone 11 ezh2, by BD (2 mentions) Cd3 clone hit3a, by BD (2 mentions) Cd4 clone rpa t4, by BD (2 mentions) Cd8 clone hit8a, by BD (2 mentions) Cd45ro clone uchl1, by BD (2 mentions) Cd62l clone dreg56, by BD (2 mentions) Cd45ra clone hi100, by BD (2 mentions) Facsaria cell sorter, by BD (2 mentions) Diva software, by BD (2 mentions)

2 protocols using klrg 1 clone 13f12f2

1

Multiparametric Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were first stained extracellularly with specific antibodies against human CD3 (clone HIT3a), CD4 (clone RPA-T4), CD8 (clone HIT8a), CD45RA (clone HI100), CD45RO (clone UCHL1), CD57 (clone NK-1), CD62L (clone DREG56) (BD Bioscience), KLRG-1 (clone 13F12F2, eBioscience) and Tim-3 (clone #344823) (R&D), were fixed and permeabilized with Fixation/Permeabilization solution (eBioscience), and finally were stained intracellularly with anti-tumor necrosis factor (TNF, clone Mab11), anti-IFN-γ (clone B27), anti-granzyme B (clone GB11), anti-Bcl-2 (clone Bcl-2/100), and anti-EZH2 (clone 11/EZH2) (BD Biosciences). Samples were acquired on a flow cytometry analyzer (LSR II; BD Biosciences) and data were analyzed with DIVA software (BD Biosciences). For lentivirus-infected cells, GFP+ cells were sorted with a FACSAria cell sorter (BD Biosciences).
Zhao E., Maj T., Kryczek I., Li W., Wu K., Zhao L., Wei S., Crespo J., Wan S., Vatan L., Szeliga W., Shao I., Wang Y., Liu Y., Varambally S., Chinnaiyan A.M., Welling T.H., Marquez V.E., Kotarski J., Wang H., Wang Z., Zhang Y., Liu R., Wang G, & Zou W. (2015). Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature immunology, 17(1), 95-103.
+ Open protocol
+ Expand
2

Multiparametric Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were first stained extracellularly with specific antibodies against human CD3 (clone HIT3a), CD4 (clone RPA-T4), CD8 (clone HIT8a), CD45RA (clone HI100), CD45RO (clone UCHL1), CD57 (clone NK-1), CD62L (clone DREG56) (BD Bioscience), KLRG-1 (clone 13F12F2, eBioscience) and Tim-3 (clone #344823) (R&D), were fixed and permeabilized with Fixation/Permeabilization solution (eBioscience), and finally were stained intracellularly with anti-tumor necrosis factor (TNF, clone Mab11), anti-IFN-γ (clone B27), anti-granzyme B (clone GB11), anti-Bcl-2 (clone Bcl-2/100), and anti-EZH2 (clone 11/EZH2) (BD Biosciences). Samples were acquired on a flow cytometry analyzer (LSR II; BD Biosciences) and data were analyzed with DIVA software (BD Biosciences). For lentivirus-infected cells, GFP+ cells were sorted with a FACSAria cell sorter (BD Biosciences).
Zhao E., Maj T., Kryczek I., Li W., Wu K., Zhao L., Wei S., Crespo J., Wan S., Vatan L., Szeliga W., Shao I., Wang Y., Liu Y., Varambally S., Chinnaiyan A.M., Welling T.H., Marquez V.E., Kotarski J., Wang H., Wang Z., Zhang Y., Liu R., Wang G, & Zou W. (2015). Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature immunology, 17(1), 95-103.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!